BACKGROUND Patients with BRAF V600E mutant metastatic colorectal cancer(mCRC)have a low incidence rate,poor biological activity,suboptimal response to conventional treatments,and a poor prognosis.In the previous cohor...BACKGROUND Patients with BRAF V600E mutant metastatic colorectal cancer(mCRC)have a low incidence rate,poor biological activity,suboptimal response to conventional treatments,and a poor prognosis.In the previous cohort study on mCRC conducted by our team,it was observed that integrated Chinese and Western medicine treatment could significantly prolong the overall survival(OS)of patients with colorectal cancer.Therefore,we further explored the survival benefits in the population with BRAF V600E mutant mCRC.AIM To evaluate the efficacy of integrated Chinese and Western medicine in the treatment of BRAF V600E mutant metastatic colorectal cancer.METHODS A cohort study was conducted on patients with BRAF V600E mutant metastatic colorectal cancer admitted to Xiyuan Hospital of China Academy of Chinese Medical Sciences and Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region from January 2016 to December 2022.The patients were divided into two cohorts.RESULTS A total of 34 cases were included,with 23 in Chinese-Western medicine cohort(cohort A)and 11 in Western medicine cohort(cohort B).The median overall survival was 19.9 months in cohort A and 14.2 months in cohort B,with a statistically significant difference(P=0.038,hazard ratio=0.46).The 1-3-year survival rates were 95.65%(22/23),39.13%(9/23),and 26.09%(6/23)in cohort A,and 63.64%(7/11),18.18%(2/11),and 9.09%(1/11)in cohort B,respectively.Subgroup analysis showed statistically significant differences in median OS between the two cohorts in the right colon,liver metastasis,chemotherapy,and first-line treatment subgroups(P<0.05).CONCLUSION Integrated Chinese and Western medicine can prolong the survival and reduce the risk of death in patients with BRAF V600E mutant metastatic colorectal cancer,with more pronounced benefits observed in patients with right colon involvement,liver metastasis,combined chemotherapy,and first-line treatment.展开更多
目的:探讨罗汉果皂苷V(MV)对铁死亡诱导剂RAS选择性致死分子3(RSL3)诱导的人神经母细胞瘤SH-SY5Y细胞铁死亡的抑制作用及可能机制。方法:用RSL3诱导SH-SY5Y细胞建立铁死亡模型。MTT法检测细胞活力;倒置显微镜观察细胞形态;亚铁离子荧光...目的:探讨罗汉果皂苷V(MV)对铁死亡诱导剂RAS选择性致死分子3(RSL3)诱导的人神经母细胞瘤SH-SY5Y细胞铁死亡的抑制作用及可能机制。方法:用RSL3诱导SH-SY5Y细胞建立铁死亡模型。MTT法检测细胞活力;倒置显微镜观察细胞形态;亚铁离子荧光探针FerroFarRed检测细胞内亚铁离子含量;线粒体红色荧光探针MitoTracker Red CMXRos检测线粒体膜电位(MMP);超氧化物阴离子荧光探针二氢乙啶和线粒体超氧化物红色荧光探针MitoSoX Red分别检测细胞内和线粒体内活性氧(ROS)。微板法检测细胞谷胱甘肽(GSH)和丙二醛(MDA)水平。Western blot检测脂酰辅酶A合成酶长链家族成员4(ACSL4)、环加氧酶2(COX-2、)谷胱甘肽过氧化物酶4(GPX4)和溶质载体家族7成员11(SLC7A11)蛋白表达水平。分子对接技术预测MV与ACSL4、COX-2、GPX4和SLC7A11的靶向关系。结果:与control组相比,RSL3组SH-SY5Y细胞活力显著降低(P<0.01),细胞内亚铁离子含量、细胞内和线粒体内ROS水平及MDA水平显著升高(P<0.05或P<0.01),MMP和GSH水平显著降低(P<0.01),ACSL4和COX-2蛋白表达水平显著升高,而GPX4和SLC7A11蛋白表达水平显著降低(P<0.01),提示成功建立了细胞铁死亡模型。MV处理使细胞活力显著升高(P<0.05),细胞内亚铁离子含量、细胞内和线粒体内ROS水平及MDA水平显著降低(P<0.01),MMP和GSH水平显著升高(P<0.05或P<0.01);ACSL4和COX-2蛋白水平显著降低,而GPX4和SLC7A11蛋白水平显著升高(P<0.05或P<0.01)。分子对接结果显示,MV与铁死亡核心蛋白ACSL4、COX-2、GPX4和SLC7A11存在结合位点。结论:MV可抑制RSL3诱导的SH-SY5Y细胞铁死亡的发生,其机制可能与激活SLC7A11/GPX4和抑制ACSL4/COX-2有关。展开更多
基金Supported by National Natural Science Foundation of China,No.82174461Hospital Capability Enhancement Project of Xiyuan Hospital,CACMS,No.XYZX0201-22Technology Innovation Project of China Academy of Chinese Medical Sciences,No.CI2021A01811.
文摘BACKGROUND Patients with BRAF V600E mutant metastatic colorectal cancer(mCRC)have a low incidence rate,poor biological activity,suboptimal response to conventional treatments,and a poor prognosis.In the previous cohort study on mCRC conducted by our team,it was observed that integrated Chinese and Western medicine treatment could significantly prolong the overall survival(OS)of patients with colorectal cancer.Therefore,we further explored the survival benefits in the population with BRAF V600E mutant mCRC.AIM To evaluate the efficacy of integrated Chinese and Western medicine in the treatment of BRAF V600E mutant metastatic colorectal cancer.METHODS A cohort study was conducted on patients with BRAF V600E mutant metastatic colorectal cancer admitted to Xiyuan Hospital of China Academy of Chinese Medical Sciences and Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region from January 2016 to December 2022.The patients were divided into two cohorts.RESULTS A total of 34 cases were included,with 23 in Chinese-Western medicine cohort(cohort A)and 11 in Western medicine cohort(cohort B).The median overall survival was 19.9 months in cohort A and 14.2 months in cohort B,with a statistically significant difference(P=0.038,hazard ratio=0.46).The 1-3-year survival rates were 95.65%(22/23),39.13%(9/23),and 26.09%(6/23)in cohort A,and 63.64%(7/11),18.18%(2/11),and 9.09%(1/11)in cohort B,respectively.Subgroup analysis showed statistically significant differences in median OS between the two cohorts in the right colon,liver metastasis,chemotherapy,and first-line treatment subgroups(P<0.05).CONCLUSION Integrated Chinese and Western medicine can prolong the survival and reduce the risk of death in patients with BRAF V600E mutant metastatic colorectal cancer,with more pronounced benefits observed in patients with right colon involvement,liver metastasis,combined chemotherapy,and first-line treatment.
文摘目的:探讨罗汉果皂苷V(MV)对铁死亡诱导剂RAS选择性致死分子3(RSL3)诱导的人神经母细胞瘤SH-SY5Y细胞铁死亡的抑制作用及可能机制。方法:用RSL3诱导SH-SY5Y细胞建立铁死亡模型。MTT法检测细胞活力;倒置显微镜观察细胞形态;亚铁离子荧光探针FerroFarRed检测细胞内亚铁离子含量;线粒体红色荧光探针MitoTracker Red CMXRos检测线粒体膜电位(MMP);超氧化物阴离子荧光探针二氢乙啶和线粒体超氧化物红色荧光探针MitoSoX Red分别检测细胞内和线粒体内活性氧(ROS)。微板法检测细胞谷胱甘肽(GSH)和丙二醛(MDA)水平。Western blot检测脂酰辅酶A合成酶长链家族成员4(ACSL4)、环加氧酶2(COX-2、)谷胱甘肽过氧化物酶4(GPX4)和溶质载体家族7成员11(SLC7A11)蛋白表达水平。分子对接技术预测MV与ACSL4、COX-2、GPX4和SLC7A11的靶向关系。结果:与control组相比,RSL3组SH-SY5Y细胞活力显著降低(P<0.01),细胞内亚铁离子含量、细胞内和线粒体内ROS水平及MDA水平显著升高(P<0.05或P<0.01),MMP和GSH水平显著降低(P<0.01),ACSL4和COX-2蛋白表达水平显著升高,而GPX4和SLC7A11蛋白表达水平显著降低(P<0.01),提示成功建立了细胞铁死亡模型。MV处理使细胞活力显著升高(P<0.05),细胞内亚铁离子含量、细胞内和线粒体内ROS水平及MDA水平显著降低(P<0.01),MMP和GSH水平显著升高(P<0.05或P<0.01);ACSL4和COX-2蛋白水平显著降低,而GPX4和SLC7A11蛋白水平显著升高(P<0.05或P<0.01)。分子对接结果显示,MV与铁死亡核心蛋白ACSL4、COX-2、GPX4和SLC7A11存在结合位点。结论:MV可抑制RSL3诱导的SH-SY5Y细胞铁死亡的发生,其机制可能与激活SLC7A11/GPX4和抑制ACSL4/COX-2有关。